ToB Business Page · Inflammatory Skin Conditions

How T cell-derived immune regulatory signaling system studies key pathways in immune signalling and barrier imbalance

This page keeps the mechanism content, while serving both partnership validation and material procurement decisions.

Open Partnership View Materials

Th2 / Th17 Elevated

Helps judge whether a collaboration entry point exists

Treg Deficient

Helps define the immune-homeostasis research direction

Barrier Disrupted

Signals material and program fit

Hormone-free

Useful for professional procurement and longer programs

Target Users

This inflammatory-skin page serves both partners and procurement teams

Start with user type, then move into the mechanism so the same content can be reused across different business conversations.

ToB Partnership

Joint validation, program onboarding, partnership discussion

For medical organizations, brand partners, and channels that need to decide whether to proceed to joint validation or co-built programs.

Check mechanism fit
Spot co-build entry points
Move the discussion forward

ToB Material Sales / Procurement

Specification review, sample confirmation, recurring procurement

For clinics, functional medicine practices, and procurement teams focused on whether the material fits their own program scenarios.

Evaluate fit
Support samples and pricing
Enable recurring buy decisions

Candidate mechanisms and validation pathways

Candidate mechanisms and validation logic for inflammatory skin conditions

The four pathways below preserve the research logic while making it easier for partners and procurement teams to understand why the page deserves follow-up.

Pathological Basis

The immune imbalance underlying inflammatory skin conditions

Eczema (atopic dermatitis) is primarily Th2-biased — excess IL-4/IL-13 damages the skin barrier and promotes IgE production. Psoriasis is centered on Th17 bias — IL-17A/TNF-α drives aberrant keratinocyte proliferation. While these two imbalance states target different pathways, both share insufficient Treg function, a failed immune tolerance braking system, and persistent skin barrier damage under chronic inflammation.

Th2 elevated (eczema)Th17 elevated (psoriasis)Treg deficiencyPersistent barrier damage

Immune Signal Observation

Observing Th2/Th17 and pro-inflammatory factor markers

The research observes miR-155, miR-146a, NF-κB, IL-4, IL-13, IL-17A and TNF-α in defined models, alongside dendritic-cell and macrophage markers, to examine candidate mechanisms.

IL-4 / IL-13IL-17A / TNF-αNF-κB pathwaymiR-155 / miR-146a

Tolerance Marker Research

Observing Treg-associated immune tolerance markers

The research observes regulatory T cell (Treg) markers and local immune tolerance signals in defined models, alongside inflammatory and barrier markers. These findings inform discussion of candidate mechanisms and are not directly extrapolated to changes in recurrence rates in people.

Treg markersImmune tolerance signalsInflammatory markersBarrier markers

Barrier Marker Observation

Observing tight-junction, barrier-protein and lipid markers

The research observes Claudin-1, Occludin, Filaggrin, barrier lipids and functional markers alongside inflammatory markers to examine candidate relationships between the barrier and the inflammatory microenvironment.

Claudin-1 / OccludinFilaggrinBarrier lipidsFunctional markers

Core research focus

Immune signalling, barrier integrity and the inflammatory microenvironment

This page forms part of our medical research collaboration section. Its content supports discussion of preclinical mechanisms and joint research; it is not a treatment recommendation, a clinical conclusion or a product performance claim.

Published research

Published research sources and evidence boundaries

The sources below provide published research context for candidate mechanisms and evaluation markers relevant to atopic dermatitis and psoriasis. They do not establish equivalent effects for AOWEISI materials and do not constitute treatment or product-performance claims.